Microglial replacement in a Sandhoff disease mouse model reveals myeloid-derived β-hexosaminidase is necessary for neuronal health
Kate I. Tsourmas, Claire A. Butler, Nellie Kwang, Zachary R. Sloane, Koby J. G. Dykman, Ghassan O. Maloof, Biswa Choudhury, Mousumi Paulchakrabarti, Christiana A. Prekopa, Emily Tabaie, Robert P. Krattli, Sanad M. El-Khatib, Vivek Swarup, Munjal M. Acharya, Lindsay A. Hohsfield, Kim N. Green
Abstract
Abstract Lysosomal storage disorders (LSDs) are a large disease class involving lysosomal dysfunction, often resulting in neurodegeneration. Sandhoff disease (SD) is an LSD caused by a deficiency in the β subunit of the β-hexosaminidase enzyme ( Hexb ). Although Hexb expression in the brain is specific to microglia, SD primarily affects neurons. To investigate how a microglial gene is involved in neuronal homeostasis, here we show that β-hexosaminidase is secreted by microglia and integrated into the lysosomal compartment of neurons. To assess therapeutic relevance, we treat the Hexb -/- SD mouse model with bone marrow transplant and colony stimulating factor 1 receptor inhibition, which broadly replaces Hexb -/- microglia with Hexb -sufficient cells. Microglial replacement reverses apoptotic gene signatures, improves behavior, restores β-hexosaminidase enzymatic activity and Hexb expression, prevents substrate buildup, and normalizes neuronal lysosomal phenotypes, underscoring the critical role of myeloid-derived β-hexosaminidase in maintaining neuronal health and establishing microglial replacement as a potential LSD therapy.